Repligen Corporation RGEN

Company Overview

Repligen Corporation is a life sciences company that develops and commercializes bioprocessing technologies used in the production of biologic drugs. The company operates within the biopharmaceutical manufacturing and life sciences tools industries, supplying critical components and systems that enable the efficient, scalable, and compliant production of biologics such as monoclonal antibodies, vaccines, cell and gene therapies, and recombinant proteins. Repligen’s offerings are primarily consumable or recurring-use products, which are closely tied to customer production volumes.

The company’s core revenue drivers include downstream purification technologies, fluid management solutions, and process analytics. Repligen serves biopharmaceutical manufacturers, contract development and manufacturing organizations (CDMOs), and research institutions, with a strong emphasis on late-stage clinical and commercial-scale production. Founded in 1981, Repligen originally focused on protein-based therapeutics before transitioning in the 2010s toward a pure-play bioprocessing tools provider through divestitures and targeted acquisitions, significantly reshaping its strategic focus and growth profile.